Nanotechnology in Metformin Delivery: Fasting Blood Glucose and Neutrophil-Lymphocyte Ratio of Diabetic Rat Model
DOI:
https://doi.org/10.18196/mmjkk.v22i1.13358Keywords:
Diabetes Mellitus, Metformin, Nanoparticles, Neutrophil-lymphocyte RatioAbstract
Diabetes Mellitus (DM) is a chronic inflammatory disease characterized by hyperglycemia and increasing the neutrophil-lymphocyte ratio (NLR). Metformin has been widely used to treat hyperglycemia. Metformin nanoparticles can improve bioavailability and may reduce inflammation. This study aims to analyze the effectiveness of metformin nanoparticles delivery through fasting blood glucose (FGB) level and NLR in the diabetic rat model. This study used 16 white male Wistar rats, 8 weeks of age, and body weight (BW) 250-350 grams. The streptozotocin (STZ) 40 mg/kg BW were injected i.p. Rats were divided into 4 groups; K1: normal control; K2: negative control (diabetes model); K3: diabetes model treated with metformin 100mg/Kg BW; K4: diabetes model treated with nanoparticle metformin 100mg/kg BW. Blood analysis tests were conducted using the Pentra hematology analyzer. Data were analyzed using the Graphpad Prism program with the nonparametric Kruskal Wallis test. The K3 group showed a periodical decrease in FBG level from day 7 to day 28 by 122 ± 11.31 mg/dL, and the mean NLR value was 0.48 ± 0.3 x 103/uL. Group of K4 periodically decreased in FBG level, indicating that it was closer to normal than K3. The result showed that at day 28.79 ± 15.39 mg/dL, the mean NLR value slightly increased compared to the K3 group by 0.54 ± 0.3 x103/uL. The statistical tests showed a significant difference between the level of FBG (p 0.0089) but no significant difference in NLR (p 0.347). Metformin nanoparticles could decrease FBG levels and effectively reduce the NLR in the diabetic rat model.References
International Diabetes Federation. 2013. IDF Diabetes Atlas sixth edition. IDF: Brussels.
World Health Organization. (2014). Diabetes Mellitus. WHO News: Fact Sheet. WHO: Geneva.
Wibisana KA, Subekti I, Antono D, dan Nugroho P. Hubungan antara Rasio Neutrofil Limfosit dengan Kejadian Penyakit Arteri Perifer Ekstremitas Bawah pada Penyandang Diabetes Melitus Tipe 2. Jurnal Penyakit Dalam Indonesia. 2018:5(4)184-188. http://dx.doi.org/10.7454/jpdi.v5i4.227
Hongdiyanto A, dan Yamlean PVY. Evaluasi Kerasionalan Pengobatan Diabetes Melitus Tipe 2 pada Pasien Rawat Inap di RSUP Prof. Dr. R. D. Kandou Manado Tahun 2013. Pharmacon. 2014:3(2):77-86. https://doi.org/10.35799/pha.3.2014.4775
Janić M, Volčanšek Š, Lunder M, and Janež A. 2017. Metformin: from mechanisms of action to advanced clinical use. Zdrav Vestn. 2017:86:138-1457. https://doi.org/10.6016/ZdravVestn.1503
Alhalmi A, Alzubaidi N, and Abdulmalik W. Current Advances in Nanotechnology for Delivery of Anti-Diabetic Drugs: A Review. Int J Pharmacog. 2018:5(1):1-7. https://doi.org/10.13040/IJPSR.0975-8232.IJP.5(1).1-07
Pereira A, Brito G, Lima M, Silva Júnior A, Silva E, de Rezende A, et al. Metformin Hydrochloride-Loaded PLGA Nanoparticle in Periodontal Disease Experimental Model Using Diabetic Rats. Int J Mol Sci. 2018:19(11)3488. https://doi.org/10.3390/ijms19113488
Hasanah A. Efek Jus Bawang Bombay (Alium cepa Linn.) terhadap Mortalitas Spermatozoa Mencit yang Diinduksi Streptozotocin (STZ). Saintika Medika: Jurnal Ilmu Kesehatan dan Kedokteran Keluarga. 2015;11(2):92-101. https://doi.org/10.22219/sm.v11i2.4203
Putra RJS, Achmad A, dan Rachma H. Kejadian Efek Samping Potensial Terapi Obat Anti Diabetes Pasien Diabetes Melitus Berdasarkan Algoritma Naranjo. Pharmeceutical Journal of Indonesia. 2017:2(2):45-50.
Zufry H. Terapi Farmakologis pada Obesitas. Jurnal Kedokteran Syiah Kuala. 2010:10(3):157-168.
Saputra TN, Suartha N, dan Dharmayudha OGAA. Agen Diabetogenik Streptozotocin untuk Membuat Tikus Putih Jantan Diabetes Melitus. Buletin Veteriner Udayana. 2018;10(2):116-121. https://doi.org/10.24843/bulvet.2018.v10.i02.p02
Katzung B.G. Farmakologi Dasar dan Klinik. EGC: Jakarta. 2016.
Fitria L, dan Sarto M. Profil Hematologi Tikus (Rattus norvegicus Berkenhout, 1769) Galur Wistar Jantan dan Betina Umur 4, 6, dan 8 Minggu. Biogenesis. 2014:2, 2(2):94–100. https://doi.org/10.24843/bulvet.2018.v10.i02.p02
Cameron AR , Morrison VL, Levin D, Mohan M, Forteath C, Beall C, et al. Antiinflamatory Effect of Metformin Irrespective of Diabetes Status. Circ Res. 2016. 1(19):652-665. https://doi.org/10.1161/CIRCRESAHA.116.308445
Wang X, Zhang G, Jiang X, Zhu H, Lu Z, and Xu L. Neutrophil to Lymphocyte Ratio in Relation to Risk of All-Cause Mortality and Cardiovascular Events among Patients undergoing Angiopraphy or Cardiac Revascularization: A Meta-Analysis of Observational Studies. Atherosclerosis. 2014: 234:206-213. https://doi.org/10.1016/j.atherosclerosis.2014.03.003
Ip B, Clifone N, Zhu M, Kuchibhatla RA, Zer M, McDonnell M, et al. An Inflammatory T Cell Signature Predicts Obesity Associated Type 2 Diabetes. J. Immunol, 2015; 1-94: 121-122.
Wong AKF, Symon R, Alzadjali MA, Ang DSC, Ogston S, Choy AM, et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eruopean Journal of Heart Failure. 2012:14:1303-1310. https://doi.org/10.1093/eurjhf/hfs106
Vasamsetti SB, Karnevewar S, Kanugula AK, Thatipali AR, Kumar JM, Kotamraju S. Metformin Inhibits Monocyte to Macrophage Differentiation Via AMPK Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis. Diabetes. 2015; 64:2028-2041. https://doi.org/10.2337/db14-1225
Rena G, Hardie G, and Pearson ER. The Mechanism of Action of Metformin. Diabetologia. 2017; 601:1577-1585. https://doi.org/10.1007/s00125-017-4342-z
Griffin SJ, Leaver JK, Irving GJ. Impact of Metformin on Cardiovascular Disease: A Meta-analysis of Randomised Trials among People with Type 2 Diabetes. Diabetologia. 2017; 60(9):1620-1629. https://doi.org/10.1007/s00125-017-4337-9
Downloads
Published
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
